New Drug Approvals Archive - February 2006
Get news by email or subscribe to our news feeds.
February 2006
| February 3 |
RotaTeq (rotavirus vaccine, live, oral, pentavalent)Date of Approval: February 3, 2006 RotaTeq (rotavirus vaccine, live, oral, pentavalent) is an oral, three-dose vaccine given to infants between the ages of six to 32 weeks for the prevention of rotavirus gastroenteritis, a leading cause of severe diarrhea in infants and young children. RotaTeq (rotavirus vaccine, live, oral, pentavalent) FDA Approval History |
| February 16 |
Vusion (miconazole nitrate, zinc oxide and white petrolatum) Ointment - formerly ZimycanDate of Approval: February 16, 2006 Vusion (miconazole nitrate, zinc oxide and white petrolatum) is a steroid-free ointment for the treatment of diaper dermatitis. Vusion (miconazole nitrate, zinc oxide and white petrolatum) FDA Approval History |
| February 17 |
Eraxis (anidulafungin) InjectionDate of Approval: February 17, 2006 Eraxis (anidulafungin) is an antifungal medicine of the echinocandin class, indicated for the treatment of candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis) and esophageal candidiasis. |
| February 17 |
Loestrin 24 Fe (norethindrone acetate/ethinyl estradiol and ferrous fumarate) TabletsDate of Approval: February 17, 2006 Loestrin 24 Fe (norethindrone acetate/ethinyl estradiol and ferrous fumarate) is an oral contraceptive providing 24 days of active hormonal therapy with four days of iron containing placebo pills. Loestrin 24 Fe is indicated for the prevention of pregnancy. Loestrin 24 Fe (norethindrone acetate/ethinyl estradiol and ferrous fumarate) FDA Approval History |
| February 27 |
Emsam (selegiline) Transdermal SystemDate of Approval: February 27, 2006 Emsam is a transdermal patch containing the monoamine oxidase inhibitor selegiline. Emsam is indicated for the treatment of major depressive disorder (MDD) in adults. |
